Cargando…

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

INTRODUCTION: The safety profile of adalimumab was previously reported in 23,458 patients across multiple indications. Here we report the long-term safety of adalimumab in adults with plaque psoriasis (Ps), hidradenitis suppurativa (HS), rheumatoid arthritis (RA), ankylosing spondylitis, psoriatic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R., Gordon, Kenneth B., Rosenbaum, James T., Arikan, Dilek, Lau, Winnie L., Li, Peigang, Faccin, Freddy, Panaccione, Remo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979455/ https://www.ncbi.nlm.nih.gov/pubmed/31748904 http://dx.doi.org/10.1007/s12325-019-01145-8

Ejemplares similares

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Age‐related structural and functional variations in 5,967 individuals across the adult lifespan
por: Luo, Na, et al.
Publicado: (2019)

Correction to Lancet Oncol 2015; 16: 967–78
Publicado: (2015)

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry
por: Loftus, Edward V, et al.
Publicado: (2019)

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
por: Burmester, G R, et al.
Publicado: (2009)

Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases
por: Elewaut, Dirk, et al.
Publicado: (2021)

Genetics, structure, and prevalence of FP967 (CDC Triffid) T-DNA in flax
por: Young, Lester, et al.
Publicado: (2015)

967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis
por: Van De Veerdonk, Frank, et al.
Publicado: (2018)

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
por: Taylor, Peter C., et al.
Publicado: (2023)

Mexiletine-like cellular electrophysiological effects of GS967 in canine ventricular myocardium
por: Hézső, Tamás, et al.
Publicado: (2021)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Guided growth: preliminary results of a multinational study of 967 physes in 537 patients
por: Danino, B., et al.
Publicado: (2018)

967. The Association between PrEP Awareness and Behavioral, Demographic, and Socioeconomic Factors in NYC
por: Adekunle, Adewumi, et al.
Publicado: (2020)

967. Interprofessional Education of Medical Students in a Comprehensive HIV Care Coordination Elective
por: Goebel, Melanie, et al.
Publicado: (2021)

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE
por: Vlachová, M., et al.
Publicado: (2022)

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies
por: Panaccione, Remo, et al.
Publicado: (2019)

Gender comparison of clinical, histopathological, therapeutic and outcome factors in 185,967 colon cancer patients
por: Schmuck, Rosa, et al.
Publicado: (2020)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Cost-Effectiveness of Tight Control for Crohn’s Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective
por: Lakatos, Peter L, et al.
Publicado: (2022)

Highly Oxygenated Constituents from a Marine Alga-Derived Fungus Aspergillus giganteus NTU967
por: Chen, Jih-Jung, et al.
Publicado: (2020)

Differential Inhibition of Human Nav1.2 Resurgent and Persistent Sodium Currents by Cannabidiol and GS967
por: Mason, Emily R., et al.
Publicado: (2020)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Clinical characteristics of 967 children with pertussis: a single-center analysis over an 8-year period in Beijing, China
por: Kang, Limin, et al.
Publicado: (2021)

P967: A MACHINE LEARNING MODEL FOR RISK PREDICTION IN MULTIPLE MYELOMA PROGRESSING AFTER THE FIRST LINE OF THERAPY
por: Mosquera-Orgueira, Adrian, et al.
Publicado: (2023)

Update on the management of inflammatory bowel disease: specific role of adalimumab
por: Guidi, Luisa, et al.
Publicado: (2011)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial
por: Inoue, Nagamu, et al.
Publicado: (2017)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
por: Hart, Ailsa, et al.
Publicado: (2022)

Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry
por: Menter, Alan, et al.
Publicado: (2017)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
por: Gabay, Cem, et al.
Publicado: (2020)

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
por: Burmester, Gerd R, et al.
Publicado: (2014)

Whole-Genome Sequencing and Comparative Genomics Analysis of a Newly Emerged Multidrug-Resistant Klebsiella pneumoniae Isolate of ST967
por: Sheng, Jie, et al.
Publicado: (2023)

Correction: Rasteiro et al. Physical Training Programs for Tactical Populations: Brief Systematic Review. Healthcare 2023, 11, 967
por: Rasteiro, André, et al.
Publicado: (2023)

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3
por: Colombel, Jean-Frederic, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ak34q89dbbfijt32hvvh8hdoo8